Persaud Navindra, Mamdani Muhammad M
University College, University of Oxford, Oxford, UK.
J Eval Clin Pract. 2006 Aug;12(4):450-3. doi: 10.1111/j.1365-2753.2006.00730.x.
Evidence that is both accurate (internally valid) and relevant (externally valid) is needed to decide which treatment is best for a particular patient. Evidence rankings facilitate the marshalling of evidence on clinical decisions in the common context of an overwhelming number of studies, some with conflicting results. Evidence from randomized control trials is typically ranked above evidence from non-experimental studies since rankings are based primarily, if not exclusively, on considerations of internal validity. We propose that evidence rankings should consider equally both internal and external validity. External validity includes how closely the study population, the institution types in the study, the types of physicians in the study, the role of clinician decision-making (e.g. dose adjustment) in the study, and the role of patient preferences in the study resemble those in actual practice. The example of spironolactone use in heart failure illustrates the danger in using evidence that is internally but not externally valid. Ideally, a treatment should only be used when both internally and externally valid evidence indicates that it will be useful for the particular patient.
要确定哪种治疗方法对特定患者最为有效,需要既准确(内部有效)又相关(外部有效)的证据。在大量研究(其中一些结果相互矛盾)的常见情况下,证据排名有助于整理有关临床决策的证据。随机对照试验的证据通常比非实验性研究的证据排名更高,因为排名主要(如果不是唯一)基于内部有效性的考量。我们建议证据排名应同等考虑内部有效性和外部有效性。外部有效性包括研究人群、研究中的机构类型、研究中的医生类型、临床医生决策(如剂量调整)在研究中的作用以及患者偏好在研究中的作用与实际临床实践中的相似程度。螺内酯用于心力衰竭的例子说明了使用内部有效但外部无效的证据的风险。理想情况下,只有当内部和外部有效证据均表明某治疗方法对特定患者有用时,才应使用该治疗方法。